Search

Copyright of Journal of Anhui Agricultural Sciences is the property of Journal of Anhui Agricultural Sciences Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To prepare anti-human IgE nanobody by phage display technology, and to establish a method for hypersensitivity detection of cat dander specific IgE antibody. Methods: Allergen bio-information of cat was searched in WHO/IUIS Allergen Database. After synthesizing sequence, recombinant cat dander allergenic protein Fel d 1 was expressed and purified in prokaryotic expression system. Human IgE was used to immunize Bactrian camel and RNA were extracted from lymphocyte to construct phage display library. Library capacity, diversity and insertion rate were analyzed, anti-human IgE nanobody were obtained by screening and identification. A magnetic particle chemical method for cat dander specific IgE antibody detection was established using recombinant allergen-coupled magnetic particles and acridine ester-labeled nanobodies. Results: Capacity of phage display library was 1.88×108 cfu/ml, insertion rate was 93.6%, and purity of nanobody was >95%. Linear range of the method based on nanobody was 0.1~100 U/ml, who was consistent with ImmunoCAP detection system by clinical data. Conclusion: Nanobody-based cat dander specific IgE antibody hypersensitivity assay is successfully prepared, providing a technical basis for auxiliary diagnosis of cat allergic diseases. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Clinical Nursing in Practice is the property of Journal of Clinical Nursing in Practice (Editorial Board, Shanghai Jiao Tong University Press) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

OBJECTIVE: To probe into the clinical efficacy of silibinin combined with entecavir in treatment of liver cirrhosis of hepatitis B. METHODS: 72 patients with liver cirrhosis of hepatitis B admitted into Ningxia People’s Hospital from Jan. 2016 to Jan. 2017 were selected and divided into observation group and control group via random number table, with 36 cases in each. The control group was treated with entecavir, while the observation group was given silibinin based on the control group. The liver function indicators, liver fibrosis indicators and incidence of adverse drug reactions of two groups were observed. RESULTS: After treatment, levels of alanine aminotransferase, prothrombin time, serum total bilirubin and albumin ol two groups were better than those of before treatment, and the observation group was better than the control group, with statistical significance (P <0.05). After treatment, the hyaluronic acid, type IV procollagen and type HI procollagen levels were better than those of before treatment, and the observation group was better than the control group, with statistical significance(P <0. 05). The incidence of adverse drug reactions of observation group was 11. 12% (4/36), significantly lower than that of control group [30.58% (1 1/36) ], with statistical significance(P <0. 05). CONCLUSIONS: The efficacy of silibinin combined with entecavir in treatment of liver cirrhosis of hepatitis B is remarkable, which can effectively improve levels of liver function indicators and liver fibrosis indicators with fewer adverse drug reactions. [ABSTRACT FROM AUTHOR]